• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ADTX

ADTX

Aditxt, Inc.

NASDAQHealthcareBiotechnologyUS

USD0.09

-0.01 (-13.57%)

Rating:C

Company Profile

CEO

Amro A. Albanna

IPO Date

2020-06-30

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.10

Prev. Close

$0.11

Day Low

$0.09

Day High

$0.11

52W Low

$0.08

52W High

$53453.52

Market Cap

$0.00B

Volume

28.42M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

34.4%

Avg Negative

1.5%

Avg Neutral

64.1%

News Feed

Aditxt's COVID-19 Test To Include Specific Antibodies To Detect Individual Immune Response; Shares Rise

Benzinga·7/12/2021·↑ positive

Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19

Business Wire·7/12/2021·↑ positive

Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors

Business Wire
·6/18/2021
·↑ positive

Aditxt Set to Join Russell Microcap® Index

PRNewsWire·6/15/2021·↑ positive

5 Penny Stocks on Reddit For Your June 2021 Watchlist

PennyStocks·5/25/2021·↓ negative

Aditxt to Establish State-of-the-Art Immune Monitoring Center in Richmond, VA

PRNewsWire·5/3/2021·↑ positive

Aditxt Therapeutics Names Sunny Uberoi as its first Chief Communications Officer

PRNewsWire·4/13/2021·↑ positive

HealthBar Becomes AditxtScore™ Channel Partner to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring to Complement its Concierge and Drive-Thru Testing Services

PRNewsWire·4/6/2021·↑ positive

Collection Sites, LLC Named AditxtScore™ Channel Partner to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring through its Mobile Testing Centers

PRNewsWire·4/1/2021·↑ positive

Aditxt to Initiate First-In-Human Clinical Trials with its Therapeutics Programs in Psoriasis by Year-End

PRNewsWire·3/24/2021·↑ positive